Veysel Karani Mah. Colakoglu Sk. No:10 Kat: 7-8-9 34885
Brief Description of the Company
The current representative of more than 50 years experience in the Turkish pharmaceutical industry, ILKO Pharmaceuticals continues its efforts to increase the stands of living in Turey nad in theworld with vanguard and innovative approaches based on its past experiences. The roots of ILKO Ilaç San ve Tic. A.S. is based on the drugstore pharmacology of the late Mr. Mustafa Öncel - one of the second generation pharmacists of Turkey - that started with magistral drug production in the 1960s and his investments in the pharmaceuticals industry. Based on the principle that the most important two factors for effectiveness in the pharmaceutical industury are R&D and production means, ILKO Pharmaceuticals established ‘ILKO Research and Development Center’ in 2009 in Hacettepe University Techno City, and the company also opened ‘ILKO Pharmaceutical Production Plants’ in 2012 in Konya 3rd Organized Industry Zone to start its operations in the pharmaceutical industry. ILKO Pharmaceuticals Production Plants is the biggest pharmaceutical industry investment realized in Anatolia so far. In 2014, ILKO Pharmaceutical Production Plants received confirmation of conformity to the European GMP (Good Manufacturing Practices) from the MHRA (Medicines and Healthcare Products Regulatory Agency of the UK). With this MHRA approval, ILKO Pharmaceuticals continues to get licenses in and export products to 25 countries located in diffrent regions. ILKO Pharmaceuticals broke ground in Turkey in December 2013 and took a step to make Turkey a player of the biotechnology market, shown as the future of the global pharmaceutical industry, by founding ILKOGEN with the partnership of South Korean biotechnology company Genexine. ILKOGEN is the first biotechnological pharmaceutical research & development, production and international marketing investment of Turkey. Furthermore, within the framework of the new attempts of ILKO Pharmaceuticals in the field of biotechnology, ILKO ARGEM Biotechnology Center was established in Istanbul Teknopark towards the end of 2014.
25,000 sqm closed area on 250.000 sqm land
Annual Production Capacity
The capacity of the plant has been planned for 120 million units per year on one shift, Current capacity is 25 million packs on one shift.
Turkey, EU (Malta), Iraq (KMCA+Kimedia), Uganda, Tanzania, Kenya, Ethiopia
ISO 14001, OHSAS 18001, Medical Devices Quality Management System ISO 13485
Number of Employees